All Online

1 - 12 of 49 results

Refine

Active filters

Infectious Diseases
girl, blowing her nose in bed speaking with physician virtually
0.36 CME CREDIT

What PCPs Need to Know About Influenza Testing (Module 1)

An Interactive Learning ExperienceThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.25 CME/MOC
0.36 AANP

Do you know when to order influenza testing (and which test) before initiating treatment in patients with influenza? Can you confidently differentiate influenza from SARS-CoV-2 infection? And can you easily identify high-risk patients who would benefit from influenza treatment or prophylaxis? Given the high cost of influenza-related morbidity and mortality to individuals and society, you have to get it right. This session will answer these questions and more and give you the confidence to accurately diagnose patients with influenza. Before you see your next patient with acute respiratory symptoms, you need to participate in this brief and innovative video-based activity that is designed to enhance learning and keep you engaged.


Physician checking on elder patient sitting on wheelchair
0.32 CME CREDIT

What PCPs Need to Know About Influenza Chemoprophylaxis (Module 3)

An Interactive Learning ExperienceThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.25 CME/MOC
0.32 AANP | 0.16 Pharmacology

In clinical trials, prophylactic treatment given at the start of an outbreak demonstrates a 60% to 90% reduction in the risk of developing influenza. However, identifying which patients would benefit most from influenza prophylaxis with antivirals is challenging. We’ll share with you clear guidance from the CDC to help you make the appropriate chemoprophylaxis decisions. After this short session, you’ll be able to identify patients who would be good candidates for antiviral prophylaxis and choose medications that best fit each patient. Before you see your next patient, you need to participate in this brief and innovative video-based activity that is designed to enhance learning and keep you engaged.


0.25 CME CREDIT

What’s New in Influenza Management? (Module 4)

An Interactive Learning ExperienceThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.25 CME/MOC
0.25 AANP | 0.07 Pharmacology

Are you aware of the recent updates in the prevention, testing, and treatment of influenza? This brief module arms you with the most important updates you’ll need to protect your patients in this upcoming influenza season. You’ll hear about the newly available quadrivalent high-dose influenza vaccine and the recently FDA-approved therapy that could potentially improve efficacy and treatment adherence while reducing transmission of influenza. You’ll also walk away with proven approaches to testing patients with acute respiratory illness—hint: it depends on what’s circulating in the community. Before you see your next patient, read through this innovative infographic that is enhanced with audio clips, questions, and additional references to enhance your learning and keep you engaged.


Teenage girl getting a vaccine in an office
0.5 CME CREDIT

Advancing HPV Cancer Prevention: The Road Towards Elimination

0.50 CME/MOC
0.50 AANP | 0.33 Pharmacology

Globally, the human papillomaviruses (HPV) is responsible for virtually 100% of cervical cancers, 75% of vaginal cancers, 69% of vulvar cancers, 91% of anal cancers, 63% of penile cancers, approximately 70% of oropharyngeal cancers, and almost all cases of genital warts. Fortunately, vaccines are available for prevention of HPV and its associated cancers. Participate in this game-based activity to learn more about the HPV vaccines, including safety & efficacy, guidelines, and dosing.


0.75 CME CREDIT

With the widespread accessibility to information on the Internet, much of which is not necessarily evidence-based, it appears that patients are more frequently consulting with their caregivers about vague somatic complaints that they think are due to exposure to various microbial organisms. Chronic Lyme disease has become a favorite disease due to some well-publicized celebrities announcing that they are suffering from this disorder. Patients also complain from the effects of mold exposure (“Toxic mold”), parasite infestations (delusions of parasitosis or Morgellon disease), among others. Patients can be very insistent, demanding therapies that are not supported by evidence. This presentation will assist practitioners as to how to appropriately diagnose and counsel patients about these various disorders.


Doctor holding heart shape stestoscope
1 CME CREDIT

Bunch of red pills
0.5 CME CREDIT

With ever-changing information on the 2019 novel coronavirus (COVID-19), it is hard to keep the facts straight! There’s new information about vaccines daily but it can be challenging to keep up. In additions there is new data on emerging treatment options. Join Drs. Charles Vega and Ty Gluckman as they team up live to discuss the most recent vaccine efficacy data, the recommendations for boosters, and the new efficacy and safety data for molnupiravir.


image of children getting vaccinated with a mask on
0.5 CME CREDIT

With ever-changing information on the 2019 novel coronavirus (COVID-19), it is hard to keep the facts straight! There’s new information about vaccines daily but it can be challenging to keep up. Join Drs. Charles Vega and Ty Gluckman as they team up live to discuss vaccines for children 5-11 years old, and vaccine-associated Myocarditis.


0.5 CME CREDIT

With ever-changing information on the 2019 novel coronavirus (COVID-19), it is hard to keep the facts straight! Join Drs. Charles Vega and Ty Gluckman as they team up live to discuss trends in substance use throughout the pandemic and common clinical questions about thrombosis and antithrombotic therapy in patients with SARS-CoV-2 infection.